NR4A1 and breast carcinoma: A total of 44 patients (64.7%) in cohort 1, 58 (79.5%) in cohort 2, and 26 (68.4%) in cohort 3 had hormone receptor-positive primary breast cancer (P = 0.13 among the three cohorts).